Presentation startup village_28_05_2013_im_slide
17
Early leukemia diagnostics Startup Village 14-05-2013 Andrey Senyut senyut@immunoslide.com
-
Upload
sergey-zasukhin -
Category
Documents
-
view
153 -
download
0
Transcript of Presentation startup village_28_05_2013_im_slide
Leukemia
Leading cause of death among children under 15
250 000 deaths per year
350 000 new cases per year
The disease is detected TOO LATE
Common methods of leukemia diagnostics are NOT SENSITIVE ENOUGH
ONLY 4% are diagnosed at the stage of preventive inspection
Problem
ImmunoSlide Affordable price
High accuracy
Immunoslide Abnormal blood cells appear in a person’s blood stream when he has leukemia.
Pathological cells differ from normal ones by:
External appearance (morphology)
Antigens on their surface (immunophenotype)
There must be no cells with “CD11C-” antigen (special protein) on their surface when a person is healthy.
Common methods of leukemia diagnostics (blood smear) don’t deliver the data about cell’s surface antigens.
Immunoslide allows doctor to receive data both on the external appearance of blood cells and on the surface antigens of blood cells.
EXAMPLE
Pathological cells
EXAMPLE
Immunoslide (disposable)
Device for an automated analysis of immunoslide
+
Product
73% margin
200 000 rubles
15% margin
300 rubles per test
ImmunoSlide
Flow cytometry
Immunocitochemistry
Blood smear
Morphological analysis (Cell outlook analysis)
++ -‐-‐ -‐ +
Immunophenotyping (Cell surface an?gens analysis)
+ ++ + -‐-‐
Cost of one test 6$ 10 – 30$ 20 – 40$ 3$ Cost of equipment 7 000$ 100 000$ -‐ -‐ Dura?on of analysis 1,5 hour 0,5 hour 3 hours 0,5 hour
Simplicity of exploita?on + -‐-‐ -‐-‐ +
Competitors
Overall market volume - 0.5 bln $
Russian market
PRIVATE MARKET GOVERNMENTAL MARKET
revenue in 5 years – 30 mln $
Required investments 2 mln $
Fazly Ataullakhanov, Member of the Na?onal Biochemical Society of Russia (1975) and Member of the Biophysical Society of USA (1997), Editorial board of “Biologicheskie Membrany” (1989), Member of the Science Council of Ins?tute for Chemical Biophysics (1997), Editorial Board of Open Journal of Structural Biology, Bentham Pub, USA and Journal of Biophysics (open access) (2007), Member of Academy of the Natural Sciences.
Igor Pivovarov, Member of execu?ve boards of several innova?ve companies. CEO of LLC “HemaCore”, the joint project with RUSNANO venture fund. HemaCore develops the unique medical equipment for precise diagnos?cs of coagula?on disorders. Igor has 5 year work experience in biotech as CTO, CMO, CEO. Raised about 660 mln. rubles of investments.
Mentors
– winner of the grant START 2012
We are Skolkovo residents
Sensi?ve
Y Y Y Y
An6gen
Immobilized an6body
Blood cell
Immunoslide
gives 10 TIMES HIGHER CHANCE of finding leukemia at it’s early stage
Devise for early leukemia diagnos?cs.
Affordable
CD 4 CD 4 CD 8 CD 8
Immunoslide
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
1 2 3 4 5 6 7 8 9
-‐40000
-‐20000
0
20000
40000
60000
80000
100000
120000
140000
1 2 3 4 5 6 7 8 9
-‐20000
0
20000
40000
60000
80000
100000
120000
140000
160000
1 2 3 4 5 6 7 8 9
Thousands of rubles
half year
NPV = 41 mln rubles, r = 40% IRR = 69%
PBP = 3.8 years Required investments
54 mln rub
CF
CF without bringing in investmnets
EBITDA
Financial forecast Thousands of rubles
Thousands of rubles
half year
half year
Ready by 80%
Prototype
No manual labor required
D. Rogachev’s children’s hematological center
Governmental clinical and diagnostic laboratories
Private clinical and diagnostic laboratories
Morozov children’s hospital
Partners
Hematological science center
